Dissemin is shutting down on January 1st, 2025

Published in

Oxford University Press, Transactions of The Royal Society of Tropical Medicine and Hygiene, 8(106), p. 508-510, 2012

DOI: 10.1016/j.trstmh.2012.05.008

Links

Tools

Export citation

Search in Google Scholar

Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

Journal article published in 2012 by Mario Ponce, Cesar Ugarte-Gil, Carlos Zamudio, Fiorella Krapp ORCID, Eduardo Gotuzzo, Carlos Seas
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p=0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.